DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

What is the SENORES PHARMACEUTICALS L (SENORES) share price today?

SENORES PHARMACEUTICALS L (SENORES) is trading at ₹1,405.1 on the NSE, down 3.29% on the day. Source: DocStoX.

What is the PE ratio of SENORES PHARMACEUTICALS L?

SENORES PHARMACEUTICALS L has a price-to-earnings (PE) ratio of 56.1 in the Healthcare sector.

What is the market capitalisation of SENORES PHARMACEUTICALS L?

SENORES PHARMACEUTICALS L has a market capitalisation of approximately ₹7,026 crore.

SENORES PHARMACEUTICALS L

SENORES·NSE·Healthcare

₹1,405.10▼ -47.80 (-3.29%)

Healthcare · Pharmaceuticals

Revenue compounding 162% a year

Day₹1392.80

₹1461.90

52W₹601

₹151088%

Open

₹1455.00

High

₹1461.90

Low

₹1392.80

Prev Close

₹1452.90

Volume

2.37L

VWAP

₹1410.20

Snapshot

Key fundamentals

Market Cap

₹7,026 Cr

P/E Ratio

56.09Expensive

P/B Ratio

6.58

EPS

₹25.05

Book Value

₹203.00

ROE

13.40%Average

ROCE

15.00%Decent

Dividend Yield

0.00%

Debt / Equity

0.37Moderate

Face Value

₹10.00

52W High

₹1509.80

52W Low

₹601.10

Sector

Healthcare

Industry

Pharmaceuticals

Avoid

None moatHigh uncertainty

Fair value estimate

₹234

▼ 83.4%downside

Trading at ₹1,405 — 83% above our estimate

BearFair valueBull

₹199₹234₹338

/100

Business quality — Solid

Growth 100Profitability 69Efficiency 18Valuation 41

Plain English

Our view

Revenue compounding 162% a year
Low debt relative to equity
Fundamental red flags (Piotroski 3/9)

Strengths

Low debt relative to equity
Revenue compounding 162% over 3 years
Profit growing 148% a year

Risks

Fundamental red flags (Piotroski 3/9)

How we got there

Fair value methods

Residual income

13% ROE fading to 13% over ~3 yrs, on ₹203 book

₹205

Relative P/E

Needs ≥3 peers with P/E

—

Graham floor

Conservative floor: √(22.5 × EPS × book value/share)

₹338

Analyst target

No analyst coverage

—

Blended fair value₹234

What the numbers say

Investment thesis

Bull case

Low debt relative to equity
Revenue compounding 162% over 3 years
Profit growing 148% a year

Bear case

Fundamental red flags (Piotroski 3/9)

Free — see our deterministic Fair Value range, business quality score, and the full bull/bear case for this stock.

Snapshot

Key statistics

P/E

56.1Expensive

Below 15× is value territory; above 35× prices in strong growth

ROE

13.4%Average

Above 15% is considered healthy for Indian equities

ROCE

15.0%Decent

Above 18% means capital is working hard

Debt/Eq

0.37Moderate

Below 0.5 is comfortable; above 1.5 strains the balance sheet

Mkt Cap

₹7,026 Cr

P/B

6.58

EPS

₹25.05

Div Yield

—

What changed

Recent changes

Foreign investors+0.3% stake last quarter
Domestic institutions+0.3% stake last quarter

What matters

News impact

Overview

Valuation

Expensive

P/E 56.1×

Growth

Strong

+162% rev CAGR

Profitability

Healthy

13.4% ROE

Financial health

Comfortable

D/E 0.37

Momentum

N/A

No technicals

Today

Trading activity

Delivery %43.0%

Turnover₹3348.14L Cr

Trades18,582

VWAP₹1410.20

Face value₹10.00

Market depth

Market depth available during market hours

Snapshot

Technical signals

Compounded annual growth

Growth (CAGR)

Revenue

+162.5%

+139.7%

10Y

—

Profit

+148.0%

+161.4%

10Y

—

EPS

+42.9%

+62.5%

10Y

—

Profile

Pros

Company is expected to give good quarter

Watch-outs

Cons

Stock is trading at 6.99 times its book value
Though the company is reporting repeated profits, it is not paying out dividend
Company has a low return on equity of 13.9% over last 3 years.
Company might be capitalizing the interest cost
Company has high debtors of 187 days.
Working capital days have increased from 67.9 days to 132 days

Forecast

News

Peers

Financials

Growth

Shareholding

Ownership

Ownership breakdown

Quarter ending 31 Mar 2026

Foreign investors bought 0.29 pts; domestic institutions added 0.30 pts last quarter. The QoQ column shows each group's change versus the prior quarter.

46%

Promoter

Promoters

45.8%+0.02

Public

31.6%-0.30

FII / FPI

3.6%+0.29

DII

9.6%+0.30

Others

9.3%

Total shareholders

34,126-275 QoQ

Quarterly trend

Ownership over time

Q4 FY26

Promoter45.82%

FII3.64%

DII9.61%

Public31.64%

Others9.29%

Corporate Actions

Bulk & Block Deals

Filings

MF Holdings

Technicals

FAQs

Quick reference

Frequently asked questions

Incorporated in 2015, Senores Pharmaceuticals Ltd manufactures and develops affordable and high-quality complex generics certified by global food and drugs authorities[1]